News
Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC) stock, maintaining a positive outlook on the company’s future. The research firm’s analyst ...
Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC) stock, maintaining a positive outlook on the company’s future. The research firm’s analyst expressed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback